tiprankstipranks
Advertisement
Advertisement

TYRA Stock Latest News

John Newman Maintains Buy Rating on Tyra with Unchanged $50 Price Target, Citing Dabogratinib’s Strong Growth Potential and Safety Profile in Achondroplasia
RatingsJohn Newman Maintains Buy Rating on Tyra with Unchanged $50 Price Target, Citing Dabogratinib’s Strong Growth Potential and Safety Profile in Achondroplasia
12d ago
TYRA
Tyra Biosciences price target lowered to $39 from $42 at BofA
PremiumThe Fly
Tyra Biosciences price target lowered to $39 from $42 at BofA
12d ago
TYRA
Tyra Biosciences price target lowered to $42 from $44 at Jefferies
PremiumThe Fly
Tyra Biosciences price target lowered to $42 from $44 at Jefferies
18d ago
TYRA
Tyra Biosciences delayed cancer data by one month, says JonesResearch
PremiumThe Fly
Tyra Biosciences delayed cancer data by one month, says JonesResearch
18d ago
TYRA
Tyra Biosciences falls 20% after pushing data readout to September from August
PremiumThe Fly
Tyra Biosciences falls 20% after pushing data readout to September from August
18d ago
TYRA
Analyst Reiterates Buy on Tyra, Maintaining $45 Price Target Ahead of Key SURF302 Phase 2 Readout
PremiumRatingsAnalyst Reiterates Buy on Tyra, Maintaining $45 Price Target Ahead of Key SURF302 Phase 2 Readout
19d ago
TYRA
Tyra Biosciences: Boris Peaker Reaffirms Buy Rating with $56 Price Target on Strength of FGFR3 Pipeline and Upcoming SURF-302/BEACH-301 Data
Premium
Ratings
Tyra Biosciences: Boris Peaker Reaffirms Buy Rating with $56 Price Target on Strength of FGFR3 Pipeline and Upcoming SURF-302/BEACH-301 Data
19d ago
TYRA
Tyra Biosciences reports Q2 EPS (69c), consensus (64c)
Premium
The Fly
Tyra Biosciences reports Q2 EPS (69c), consensus (64c)
19d ago
TYRA
Tyra Biosciences Advances First‑in‑Human TYRA‑430 Trial in FGFR‑Driven Liver and Solid Tumors
PremiumCompany Announcements
Tyra Biosciences Advances First‑in‑Human TYRA‑430 Trial in FGFR‑Driven Liver and Solid Tumors
25d ago
TYRA
Tyra Biosciences Advances TYRA-200 Into First-in-Human FGFR2 Cancer Trial
PremiumCompany Announcements
Tyra Biosciences Advances TYRA-200 Into First-in-Human FGFR2 Cancer Trial
25d ago
TYRA
Analyst Maintains Buy on Tyra Biosciences, Reiterates $50 Price Target on NMIBC Opportunity
PremiumRatings
Analyst Maintains Buy on Tyra Biosciences, Reiterates $50 Price Target on NMIBC Opportunity
1M ago
TYRA
Tyra Biosciences: Buy Rating Reaffirmed, $50 Price Target Maintained on Strong Dabogratinib Potential
PremiumRatings
Tyra Biosciences: Buy Rating Reaffirmed, $50 Price Target Maintained on Strong Dabogratinib Potential
1M ago
TYRA
Blair adds American Express, Oracle to Conviction List in monthly update
PremiumThe FlyBlair adds American Express, Oracle to Conviction List in monthly update
2M ago
P
CW
Tyra Biosciences assumed with an Outperform at Oppenheimer
Premium
The Fly
Tyra Biosciences assumed with an Outperform at Oppenheimer
2M ago
TYRA
Tyra Biosciences initiated with a Buy at JonesResearch
Premium
The Fly
Tyra Biosciences initiated with a Buy at JonesResearch
2M ago
TYRA
Tyra Biosciences price target raised to $42 from $37 at BofA
PremiumThe Fly
Tyra Biosciences price target raised to $42 from $37 at BofA
2M ago
TYRA
Analyst Initiates Buy on Tyra Biosciences, Citing De-Risked Dabogratinib Program and Attractive Entry Ahead of Key Bladder Cancer Data
PremiumRatings
Analyst Initiates Buy on Tyra Biosciences, Citing De-Risked Dabogratinib Program and Attractive Entry Ahead of Key Bladder Cancer Data
2M ago
TYRA
Tyra Biosciences Shareholders Reelect Directors and Ratify Auditor
PremiumCompany Announcements
Tyra Biosciences Shareholders Reelect Directors and Ratify Auditor
3M ago
8K
TYRA
Tyra Biosciences Rated Buy on Anticipation of Interim SURF302 Dabogratinib Data in FGFR3‑Driven NMIBC
PremiumRatings
Tyra Biosciences Rated Buy on Anticipation of Interim SURF302 Dabogratinib Data in FGFR3‑Driven NMIBC
3M ago
TYRA
Tyra Biosciences initiated with a Peer Perform at Wolfe Research
PremiumThe FlyTyra Biosciences initiated with a Peer Perform at Wolfe Research
3M ago
TYRA
Tyra Biosciences reports Q1 EPS (64c), consensus (59c)
Premium
The Fly
Tyra Biosciences reports Q1 EPS (64c), consensus (59c)
3M ago
TYRA
Analyst Reiterates Buy on Tyra as Dabogratinib Catalysts Approach; $50 Price Target Maintained
Premium
Ratings
Analyst Reiterates Buy on Tyra as Dabogratinib Catalysts Approach; $50 Price Target Maintained
3M ago
TYRA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >